Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer: A Single Center, Single Arm, Phase II Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• subjects with a histopathological or cytologically diagnosis of BTC
• The participants must be required to sign an informed consent
• At least one measurable lesion (RECIST 1.1)
• No previous systematic treatment for BTC
• Child-Pugh Score, Class A
• ECOG performance status 0 or 1
• Adequate organ function
• Life expectancy of at least 3 months
Locations
Other Locations
China
Tianjin Cancer Hospital Airport Hospital
RECRUITING
Tianjin
Time Frame
Start Date: 2023-09-01
Estimated Completion Date: 2025-09-01
Participants
Target number of participants: 30
Treatments
Experimental: Cadonilimab+rego+Gem/Cis
Related Therapeutic Areas
Sponsors
Leads: Tianjin Medical University Cancer Institute and Hospital